| http://www.w3.org/ns/prov#value | - r digestive dysfunction that would prevent administration of study therapy.Subjects who received any of the following:imatinib mesylate within 7 days;interferon or cytarabine within 14 days;a targeted small molecule anti-cancer agent within 14 days;any other investigational or antineoplastic agent other than hydroxyurea or anagrelide within 28 days before starting treatment with BMS-354825.Subject
|
